Module 5 Clinical Study Reports: Structuring Clinical Evidence for EU Assessment

Module 5 is usually the largest part of a marketing authorisation dossier, and assessors navigate it under time pressure. A complete tabular listing, study reports written to ICH E3 and correct placement of every study make the difference between an efficient review and a list of avoidable questions.

The structure of Module 5

  • 5.2 Tabular listing of all clinical studies: the map of the clinical programme.
  • 5.3.1 Biopharmaceutic studies: bioavailability, comparative bioavailability and bioequivalence studies, and in vitro–in vivo correlation.
  • 5.3.2 Studies using human biomaterials and 5.3.3 Human pharmacokinetic studies.
  • 5.3.4 Human pharmacodynamic studies.
  • 5.3.5 Efficacy and safety studies: controlled and uncontrolled studies for the claimed indication, integrated analyses and other reports.
  • 5.3.6 Post-marketing experience and 5.3.7 Case report forms and individual patient listings.
  • 5.4 Literature references.

Clinical study reports under ICH E3

ICH E3 defines the structure and content of a clinical study report: synopsis, ethics, investigators and administrative structure, study objectives and design, study population, efficacy and safety evaluation, discussion and appendices such as the protocol, sample case report forms and statistical methods. ICH has published a question-and-answer document clarifying that E3 is a guide rather than a rigid template, which gives sponsors some flexibility provided the essential information is present.

GCP and ethics statements

Each report should confirm that the study was conducted in accordance with Good Clinical Practice. For trials conducted outside the EU, Annex I of Directive 2001/83/EC requires a statement that the trials met ethical requirements equivalent to those in the EU. Applicants should also be ready to show alignment with current ICH GCP expectations, including the revised ICH E6(R3) guideline adopted by ICH in January 2025, for studies conducted after it took effect.

Common compilation issues

  • Studies listed in 5.2 but missing from 5.3, or the reverse.
  • Pivotal studies supplied as synopses only, without full reports.
  • Integrated efficacy and safety analyses with no clear link to the clinical summaries in 2.7.
  • Inconsistent study identifiers between the clinical overview, summaries and reports.
  • Bioequivalence studies for generics filed without the analytical validation and bioanalytical reports.

Planning for transparency

Clinical information submitted to EMA may be subject to publication under the agency’s transparency policies, and the Clinical Trials Regulation adds its own disclosure requirements. Reports drafted with redaction and anonymisation in mind from the outset reduce effort later.

How PQRA helps

PQRA reviews Module 5 for completeness and consistency, checks alignment with the clinical overview and summaries, and supports applicants in preparing tabular listings and clinical sections for EU and Greek submissions.

Contact PQRA to discuss your next dossier.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *